<DOC>
	<DOCNO>NCT00848120</DOCNO>
	<brief_summary>This single arm , open label study assess safety efficacy , regard reduction sign symptom , treatment tocilizumab patient moderate severe active rheumatoid arthritis . Patients receive tocilizumab 8 mg/kg IV every 4 week total 6 infusion . Patients already receive methotrexate entry study may continue treatment together tocilizumab.The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Assess Effect Tocilizumab Signs Symptoms Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; rheumatoid arthritis diagnose &gt; 8 week &lt; 4 year prior baseline ; naive , respond well , methotrexate ; swell joint count &gt; =8 ( 66 joint count ) tender joint count &gt; =8 ( 68 joint count ) screen baseline . rheumatic autoimmune disease rheumatoid arthritis ; patient functional class IV rheumatoid arthritis ; history , current , inflammatory joint disease rheumatoid arthritis , systemic autoimmune disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>